Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity
Copyright 2019, SLACK Incorporated.
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 50(2019), 4 vom: 01. Apr., Seite 228-234 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2019
|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina |
| Schlagworte: | Journal Article Research Support, N.I.H., Extramural Review Angiogenesis Inhibitors Bevacizumab 2S9ZZM9Q9V Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1 |
| Zusammenfassung: | Copyright 2019, SLACK Incorporated. Treatment of severe retinopathy of prematurity (ROP) has evolved over the last decade. This article reviews recent clinical trials and experimental evidence that supports clinical outcomes and observations, including the efficacy of anti-vascular endothelial growth factor (VEGF) agents in reducing the vascular activity of severe ROP, and the mechanisms behind recurrent stage 3 ROP and plus disease in some infants treated with anti-VEGF agents. Also discussed will be current imaging modalities that link experimental models of ROP with longitudinal human studies and which provide exciting future opportunities to enhance the understanding of pathophysiology of ROP and improve treatments. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:228-234.] |
|---|---|
| Beschreibung: | Date Completed 17.12.2019 Date Revised 17.12.2019 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20190401-05 |